The use of haloperidol and associated complications in the agitated, acutely ill pediatric burn patient

Journal of Burn Care and Rehabilitation

Volumn 25, Issue 6, 2004, Pages 472-478

  Ratcliff, Stephen L ^a,b   Meyer III, Walter J ^a,b,c   Cuervo, Luis J ^a,b   Villarreal, Cynthia ^a   Thomas, Christopher R ^a,b   Herndon, David N ^a,b  

^a SHRINERS HOSPITALS FOR CHILDREN   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZATROPINE MESILATE; BENZODIAZEPINE; CHLORAL HYDRATE; CHLORPROMAZINE; CYPROHEPTADINE; DIAZEPAM; DIPHENHYDRAMINE; FLUOXETINE; HALOPERIDOL; HYDROCODONE BITARTRATE PLUS PARACETAMOL; HYDROXYZINE; IBUPROFEN; IMIPRAMINE; LORAZEPAM; MIDAZOLAM; MORPHINE; PARACETAMOL; PETHIDINE;

ACUTE STRESS DISORDER; ADOLESCENT; AGITATION; AKATHISIA; ANXIETY DISORDER; BODY TEMPERATURE DISORDER; BURN; CHILD; DELIRIUM; DRUG EFFICACY; DRUG PREFERENCE; DRUG SAFETY; DYSTONIA; FEMALE; HUMAN; MALE; NEUROLEPTIC MALIGNANT SYNDROME; PAIN; PARKINSONISM; PRURITUS; RETROSPECTIVE STUDY; REVIEW; SEDATION; SEIZURE;

ADOLESCENT; ANTI-DYSKINESIA AGENTS; BURNS; CHILD; CRITICAL ILLNESS; DELIRIUM; DYSTONIA; FEMALE; FEVER; HALOPERIDOL; HUMANS; MALE; PSYCHOMOTOR AGITATION; RETROSPECTIVE STUDIES;

EID: 8544235025     PISSN: 02738481     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.BCR.0000144540.21272.2C     Document Type: Review

References (16)

1. Settle EC Jr, Ayd FC Jr. Haloperidol: a quarter century of experience. J Clin Psychiatry 1983;44:440-8.
2. Brown RL, Henke A, Greenhalgh DG, Warden GD. The use of haloperidol in the agitated, critically ill pediatric patient with burns. J Burn Care Rehabil 1996;17:34-8.
3. Serrano A. Haloperidol - its use in children. J Clin Psychiatry 1981;42:154-6.
4. Spies M, Muller MJ, Herndon DN. Modulation of the hypermetabolic response after burn. In: Herndon DN, editor. Total burn care. 2nd ed. New York: W.B. Saunders; 2002. p. 363-81.
5. Thomas CR, Meyer WJ III, Blakeney PE. Psychiatric disorders associated with burn injury. In: Herndon DN, editor. Total burn care. 2nd ed. New York: W.B. Saunders; 2002. p. 766-73.
6. Thomas CR, Rosenberg M, Blythe V, Meyer WJ III. Serotonin syndrome and linezolid [letter to the editor]. J Am Acad Child Adolesc Psychiatry 2004;43:790.
7. Timm E. The recognition and management of agitation in hospitalized patients. Hospital Pharmacy 1992;27: 355-60.
8. Baldessarini RJ, Tarazi FI. Drugs and the treatment of psychiatric disorders. In: Hardman JG, Limbird LE, Gilman AG, editors. Goodman and Gilman's the pharmacological basis of therapeutics. 10th ed. New York, NY: McGraw-Hill; 2001. p. 485-520.
9. Forsman AO, Ohman R. Applied pharmacokinetics of haloperidol in man. Curr Ther Res 1977;21:396-411.
10. Cressman WA, Bianchine JR, Slotnick VB, et al. Plasma level profile of haloperidol in man following intramuscular administration. Eur J Clin Pharmacol 1974;7:99-103.
11. Huang V, Figge H, Demling R. Haloperidol complications in burn patients. J Burn Care Rehabil 1987;8:269-73.
12. Schatzberg AF, Nemeroff CB. Textbook of Psychopharmacology. 1st ed. Washington, DC: American Psychiatric Press, Inc.; 1995. p. 624-34.
13. Mueller PS, Vester JW, Fermaglich J. Neuroleptic malignant syndrome - successful treatment with bromocriptine. JAMA 1983;249:386-8.
14. May DC, Morris SW, Stewart RM, et al. Neuroleptic malignant syndrome: response to dantrolene sodium. Ann Intern Med 1983;98:183-4.
15. Ayd FJ Jr. Neuroleptic-induced extrapyramidal reactions: incidence, manifestations and management. The future of pharmacotherapy - new drug delivery systems. Int Drug Ther Newsletter 1973;8:77-88.
16. Harrison AM, Lugo RA, Lee WE, et al. The use of haloperidol in agitated critically ill children. Clin Pediatr 2002;41: 51-4.